Journal article
Interferon-α and transfer factor in the treatment of multiple sclerosis: A double-blind, placebo-controlled trial
JA Frith, JG McLeod, JFBR Hallpike Chambers, G Danta, KMR Grainger, SR Hammond, G Harris, AC Reid, G Symington, JC Walsh, DB Williams, PT Yeo, IR Mackay, A Basten, J Bradley, RL Dawkins, D English, RM Lowenthal, CM Van der Brink
Journal of Neurology Neurosurgery and Psychiatry | BRITISH MED JOURNAL PUBL GROUP | Published : 1989
Abstract
The role of interferon-α (IFN-α) and transfer factor (TF) in the treatment of multiple sclerosis was investigated in a prospective, multi-centric, three year, double-blind, placebo-controlled trial. One hundred and eighty two patients with clinically definite multiple sclerosis were randomised into three treatment groups whose compositions were found to be similar for demographic and prognostic variables including HLA status. Subcutaneous injections of IFN-α (3 x 106 units), TF (0.5 units) manufactured from leucocytes of cohabiting donors, or placebo were given twice weekly for two months, once weekly for 10 months then fortnightly for 24 months. One hundred and fifty three patients complete..
View full abstract